Achieve Life Sciences shows a genuine technical breakout with an outsized reward-to-risk setup and a large analyst-target upside, but weak underlying quality and extreme options hedging keep the position capped at avoid.
Thesis pillars
- Breakout With High Asymmetry→Stable
- Quality Below Floor Exit Signal→Stable
- Steep Analyst Upside Light Coverage→Stable
- +2 more pillars — see the Why tab for full reasoning
Achieve Life Sciences, Inc. (ACHV) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.10: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company solely developing cytisinicline, a nicotine-receptor drug candidate for smoking and e-cigarette cessation, with an FDA-accepted New Drug Application carrying a PDUFA target action date of June 20,... Read more
Sell if holding. Engine safety override at $6.10: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Score 5.6/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Achieve Life Sciences, Inc.
About Achieve Life Sciences, Inc.
Achieve Life Sciences' sole product candidate, cytisinicline, has an FDA-accepted New Drug Application for smoking cessation with a PDUFA target action date of June 20, 2026, following two Phase 3 trials that randomized 1,602 adult smokers at 37 U.S. sites. A parallel vaping-cessation indication holds FDA Breakthrough Therapy designation and a Commissioner's National Priority Voucher awarded in October 2025. As of December 31, 2025, the company carried $15.0 million in debt principal and has never generated product revenue.
Achieve licenses cytisinicline's development and commercialization rights outside Central and Eastern Europe, Scandinavia, North Africa, the Middle East, Central Asia and Vietnam from Sopharma, which has marketed its own cytisinicline formulation in Central and Eastern Europe for over 20 years under an exclusive license and supply agreement. The active ingredient is derived from Faboideae-family plants that grow naturally only in the mountains of Southern Europe, Russia, China and a limited number of other locations, and Achieve is pursuing synthetic sourcing routes as a hedge against that natural-supply constraint. For U.S. commercial manufacturing, the company has partnered with Adare Pharma Solutions and commenced a technology transfer intended to add domestic supply-chain redundancy ahead of an anticipated first-half 2027 launch. Achieve has funded operations primarily through equity sales and convertible notes, carries $15.0 million in debt under an agreement with Silicon Valley Bank (now First-Citizens Bank & Trust), and is contractually required to keep substantially all of its cash and investments at that institution.
Show full overview
Achieve's fortunes rest almost entirely on a single regulatory outcome: the FDA's review of cytisinicline for smoking cessation is due by the June 20, 2026 PDUFA date, but the agency has already flagged two manufacturing observations at a third-party facility named in the NDA, creating a specific, dated risk of delay beyond that target. Because Achieve has no approved products and has stated substantial doubt about its ability to continue as a going concern, a complete response letter or an approval delay would arrive at a company with current resources insufficient to fund operations for the next 12 months, raising the odds of further dilutive financing or a strategic-alternatives process that could include a sale of assets.
See also: Healthcare · Biotechnology
From Achieve Life Sciences, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Achieve Life Sciences, Inc.
Latest news
- NEWS Achieve Life Sciences Added To Russell 2000 Index, Effective June 26 — benzinga Jun 29, 2026 positive
Generated 2026-07-08T22:53:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.10: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Prior stop was $5.78. Score 5.6/10, moderate confidence.
Take-profit target: $12.01 (+93.4% upside). Prior stop was $5.78. Stop-loss: $5.78.
Quality below floor (2.0 < 4.0).
Achieve Life Sciences, Inc. trades at a P/E of N/A (forward -13.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover ACHV with a consensus score of 4.1/5. Average price target: $14.
What does Achieve Life Sciences, Inc. do?Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company solely developing cytisinicline, a...
Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company solely developing cytisinicline, a nicotine-receptor drug candidate for smoking and e-cigarette cessation, with an FDA-accepted New Drug Application carrying a PDUFA target action date of June 20, 2026. The company has never generated product revenue, faces substantial doubt about its ability to continue as a going concern, and depends on an exclusive license and supply agreement with Sopharma plus a manufacturing partnership with Adare Pharma Solutions.